Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142

The Journal of Pharmacology and Experimental Therapeutics
Megan J MoerkeS Stevens Negus

Abstract

Drugs that inhibit the dopamine (DA) transporter (DAT) include both therapeutic agents and abused drugs. Recent studies identified a novel series of putative allosteric DAT inhibitors, but the in vivo effects of these compounds are unknown. This study examined the abuse-related behavioral and neurochemical effects produced in rats by SRI-31142 [2-(7-methylimidazo[1,2-a]pyridin-6-yl)-N-(2-phenyl-2-(pyridin-4-yl)ethyl)quinazolin-4-amine], one compound from this series. In behavioral studies, intracranial self-stimulation (ICSS) was used to compare the effects produced by SRI-31142, the abused and nonselective DAT inhibitor cocaine, and the selective DAT inhibitor GBR-12935 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine]. In neurochemical studies, in vivo microdialysis was used to compare the effects of SRI-31142 and cocaine on levels of DA and serotonin in nucleus accumbens (NAc). The effects of SRI-31142 in combination with cocaine were also examined in both procedures. In contrast to cocaine and GBR-12935, SRI-31142 failed to produce abuse-related increases in ICSS or NAc DA; instead, SRI-31142 only decreased ICSS and NAc DA at a dose that was also sufficient to block cocaine-induced increases in ICSS and NAc DA. Ph...Continue Reading

References

Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Dec 1, 1980·Journal of Neuroscience Methods·G PaxinosP C Emson
Jan 1, 1996·Annual Review of Neuroscience·R A Wise
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Paul W CzotyLeonard L Howell
Nov 16, 2006·Annals of the New York Academy of Sciences·Richard B Rothman, Michael H Baumann
Nov 17, 2007·Nature Protocols·William A Carlezon, Elena H Chartoff
Apr 29, 2008·The Journal of Pharmacology and Experimental Therapeutics·Joseph J PariserRichard B Rothman
Feb 1, 2012·The Journal of Biological Chemistry·Ernesto SolisLouis J De Felice
Dec 14, 2012·Nature·Jérémy BesnardAndrew L Hopkins
Jan 22, 2013·The Journal of Pain : Official Journal of the American Pain Society·Marisa B RosenbergS Stevens Negus
Jun 29, 2014·Pharmacological Reviews·S Stevens Negus, Laurence L Miller
Dec 31, 2014·Drug and Alcohol Dependence·Maarten E A ReithJonathan L Katz
Jan 8, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S Stevens Negus, Jack Henningfield
Mar 20, 2015·The Journal of Pharmacology and Experimental Therapeutics·Richard B RothmanMichael H Baumann
Dec 10, 2015·The Journal of Pharmacology and Experimental Therapeutics·Julie A SuyamaMatthew L Banks
Jan 27, 2017·Behavioural Pharmacology·Matthew F Lazenka, S Stevens Negus
May 23, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ernesto SolisMichael H Baumann
Mar 13, 2018·Experimental and Clinical Psychopharmacology·Farhana Sakloth, S Stevens Negus
Apr 29, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amy R JohnsonS Stevens Negus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.